Details for 2009716778

Up to date per 02.04.2026

Actions

Title / Product Name

Verwendung von 5-(2,6-Di-Morpholin-4-yl-Pyrimidin-4-yl)-4-Trifluoromethyl-Pyridin-2-ylamin zur Behandlung von nicht-kleinzelligem Bronchialkarzinom mit erworbener Resistenz gegenüber Modulatoren des EGF (Epidermal Growth Factor)-Rezeptors

Status

Deleted

Protection Type

European Patent

(AT-) Application Number

2009716778

EP Publication Number

2259800

E-Number

666092

Language

PCT Number

EP09052564

Publication Date

15.12.2010 A

07.05.2014 B1

Registration Date

07.05.2014

AT Publication Date

15.05.2014

Application Date

04.03.2009

Registration Number

Priorities

05.03.2008

08152326

IPC

A61K 45/06 20060101AFI20090929BHEP

Maximum Duration of Protection

04.03.2029

Owner

Novartis AGLichtstrasse 35 4056 BaselCH

Representative

Schwarz & Partner Patentanwälte OGWipplingerstraße 301010 WienAT

Inventor

GARCIA-ECHEVERRIA, CarlosEngelgasse 126 4052 BaselCH

MAIRA, Sauveur-Michel3c rue de Hombourg 68440 HabsheimFR